ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2003
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue protection. Key products include ORTHOVISC (osteoarthritis), ophthalmic viscoelastics (AMVISC, CoEase, STAARVISC-II, ShellGel), and HYVISC (equine osteoarthritis). ORTHOVISC is marketed internationally but remains investigational in the U.S., pending FDA Pre-Market Approval (PMA).

Key Financial Metrics

Liquidity: Cash and cash equivalents totaled $11.5 million at June 30, 2003. The company had no marketable securities at period end, having sold $2.5 million in securities during the six-month period. There is no long-term debt reported.

Material Changes vs. Prior Period

• Revenue: Q2 2003 revenue decreased 3.3% year-over-year, while the six-month period increased 15%. The Q2 decline was driven by a $300,000 drop in HYVISC sales due to customer order timing, partially offset by growth in ophthalmic products and ORTHOVISC.
• Profitability: Gross margin improved significantly to 44.4% in Q2 2003 (from 35.6% in Q2 2002) due to manufacturing efficiencies and expense controls. Net loss narrowed substantially to $81,000 in Q2 2003 compared to $1.157 million in Q2 2002.
• Operating Expenses: R&D expenses decreased 38.3% in Q2 2003, primarily due to the completion of the Phase III clinical trial for ORTHOVISC. SG&A expenses decreased 31.9%, driven by lower legal and personnel costs.
• Cash Flow: Net cash used in operating activities increased to $1.925 million for the six months ended June 30, 2003, compared to $1.119 million in the prior year, largely due to increases in accounts receivable and inventory.

Guidance, Outlook, and Risks

• Regulatory Status: Anika submitted a PMA application for ORTHOVISC to the FDA in late May 2003. Approval is required for U.S. commercial sales. The company received regulatory approval in June 2003 to use a new clean room for HYVISC manufacturing and began shipping re-released inventory.
• Customer Concentration: Revenue is heavily dependent on a few customers. For the six months ended June 30, 2003, four customers accounted for 90.5% of product revenue. Bausch & Lomb alone accounted for 43.8% of product revenue.
• Deferred Revenue: $645,000 of revenue related to Bausch & Lomb sales is deferred due to volume-based pricing adjustments that will be finalized in the fourth quarter. This creates uncertainty regarding final 2003 revenue recognition.
• Capital Resources: Management believes current cash resources are sufficient to meet requirements for at least the next twelve months. However, future profitability is uncertain, and additional financing may be required.
• Risks: Key risks include failure to obtain FDA approval for ORTHOVISC, dependence on Bausch & Lomb, volatility in international markets (specifically Turkey), and potential product liability claims.

Investor Verification Checklist

• FDA PMA Status: Verify the current status of the ORTHOVISC Pre-Market Approval application submitted in May 2003 and any FDA feedback received.
• Bausch & Lomb Agreement: Review the terms of the supply agreement with Bausch & Lomb, specifically the volume-based pricing mechanism that results in significant deferred revenue and potential rebates.
• Customer Concentration: Assess the financial stability of the top four customers, which represent over 90% of product revenue.
• Inventory Valuation: Confirm the status and sell-through of the $196,000 of re-released HYVISC inventory remaining at period end.
• Cash Burn Rate: Monitor the rate of cash consumption given the $1.9 million operating cash outflow in the first half of 2003 and the company's history of losses.